PE20140969A1 - Combinacion de analogos del glucagon acilados con analogos de insulina - Google Patents
Combinacion de analogos del glucagon acilados con analogos de insulinaInfo
- Publication number
- PE20140969A1 PE20140969A1 PE2013001533A PE2013001533A PE20140969A1 PE 20140969 A1 PE20140969 A1 PE 20140969A1 PE 2013001533 A PE2013001533 A PE 2013001533A PE 2013001533 A PE2013001533 A PE 2013001533A PE 20140969 A1 PE20140969 A1 PE 20140969A1
- Authority
- PE
- Peru
- Prior art keywords
- analogs
- arg
- combination
- leu
- ala
- Prior art date
Links
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical class C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
SE REFIERE A UNA COMBINACION DE ANALOGOS DEL GLUCAGON ACILADOS CON ANALOGOS DE INSULINA, QUE COMPRENDE UN COMPUESTO QUE TIENE LA FORMULA: R1-Z-R2, EN LA QUE R1 ES H, ALQUILO C1-C4, ACETILO, FORMILO, ENTRE OTROS; R2 ES OH, NH2; Z ES UN PEPTIDO QUE TIENE LA FORMULA: His-X2-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-X12-Tyr-Leu-Asp-X16-X17-Ala-Ala-X20-X21-Phe-Val-X24-Trp-Leu-X27-X28-Ala-X30, DONDE X2 SE SELECCIONA DE Aib, Ser; X12 SE SELECCIONA DE Lys, Arg, Leu; X16 ES Arg; X17 ES Arg; X20 SE SELECCIONA DE Arg, His; X21 SE SELECCIONA DE Asp, Glu; X24 SE SELECCIONA DE Ala, X; X27 SE SELECCIONA DE Leu Y X; X28 SE SELECCIONA DE Arg, X; X30 ES X, EN LA QUE CADA RESTO X SE SELECCIONA DEL GRUPO DE Glu, Lys, Ser, Cys, ENTRE OTROS. DICHA COMBINACION DE COMPUESTOS ES UTIL EN PROCEDIMIENTO PARA PREVENIR EL AUMENTO DE PESO, REDUCIR LOS NIVELES DE LDL EN CIRCULACION, ENTRE OTROS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161434698P | 2011-01-20 | 2011-01-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20140969A1 true PE20140969A1 (es) | 2014-07-24 |
Family
ID=45607302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013001533A PE20140969A1 (es) | 2011-01-20 | 2012-01-20 | Combinacion de analogos del glucagon acilados con analogos de insulina |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20140011733A1 (es) |
| EP (1) | EP2665487A1 (es) |
| JP (1) | JP2014504597A (es) |
| KR (1) | KR20140043709A (es) |
| CN (1) | CN103491975B (es) |
| AR (1) | AR085086A1 (es) |
| AU (1) | AU2012208349A1 (es) |
| BR (1) | BR112013018269A2 (es) |
| CA (1) | CA2824397A1 (es) |
| CL (1) | CL2013002085A1 (es) |
| CO (1) | CO6761400A2 (es) |
| EA (1) | EA201390796A1 (es) |
| MA (1) | MA34913B1 (es) |
| MX (1) | MX2013008005A (es) |
| PE (1) | PE20140969A1 (es) |
| PH (1) | PH12013501495A1 (es) |
| SG (1) | SG192038A1 (es) |
| TN (1) | TN2013000251A1 (es) |
| TW (1) | TW201247702A (es) |
| UY (1) | UY33872A (es) |
| WO (1) | WO2012098462A1 (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010070255A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| WO2010070251A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| AU2008365556A1 (en) | 2008-12-15 | 2011-07-21 | Zealand Pharma A/S | Glucagon analogues |
| WO2010070253A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| CN104961822A (zh) | 2009-07-13 | 2015-10-07 | 西兰制药公司 | 酰化胰高血糖素类似物 |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| AU2011269430A1 (en) | 2010-06-24 | 2013-01-10 | Zealand Pharma A/S | Glucagon analogues |
| EP2758426B1 (en) | 2011-09-23 | 2019-08-07 | Novo Nordisk A/S | Novel glucagon analogues |
| EA028665B1 (ru) | 2012-05-03 | 2017-12-29 | Зилэнд Фарма А/С | Соединения - двойные агонисты gip-glp-1 и способы |
| JP6534927B2 (ja) | 2012-07-23 | 2019-06-26 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| TWI608013B (zh) * | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| EP2970511B1 (en) * | 2013-03-14 | 2020-09-30 | Indiana University Research and Technology Corporation | Insulin-incretin conjugates |
| WO2014170496A1 (en) | 2013-04-18 | 2014-10-23 | Novo Nordisk A/S | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
| CN119119233A (zh) | 2013-10-17 | 2024-12-13 | 西兰制药公司 | 酰化胰高血糖素类似物 |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| KR102310392B1 (ko) | 2013-11-06 | 2021-10-13 | 질랜드 파마 에이/에스 | 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물 |
| CA2929459C (en) | 2013-11-06 | 2022-05-03 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| AR098616A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
| EP3098235A4 (en) | 2014-01-20 | 2017-10-18 | Hanmi Pharm. Co., Ltd. | Long-acting insulin and use thereof |
| AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| AR100695A1 (es) | 2014-05-30 | 2016-10-26 | Hanmi Pharm Ind Co Ltd | Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón |
| WO2015185640A1 (en) | 2014-06-04 | 2015-12-10 | Novo Nordisk A/S | Glp-1/glucagon receptor co-agonists for medical use |
| JP6657230B2 (ja) | 2014-09-24 | 2020-03-04 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | インクレチン−インスリンコンジュゲート |
| KR102620911B1 (ko) | 2014-10-29 | 2024-01-05 | 질랜드 파마 에이/에스 | Gip 효능제 화합물 및 방법 |
| AU2016247499B2 (en) | 2015-04-16 | 2020-09-03 | Zealand Pharma A/S | Acylated glucagon analogue |
| UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| BR102015031283A2 (pt) * | 2015-12-14 | 2018-09-18 | Univ Rio De Janeiro | Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento |
| EP3430033A4 (en) * | 2016-03-18 | 2019-11-20 | Merck Sharp & Dohme Corp. | CONJUGATES OF INSULIN-INCRETIN |
| US11058775B2 (en) | 2016-04-26 | 2021-07-13 | Merck Sharp & Dohme Corp. | Insulin dimer-incretin conjugates |
| WO2018056764A1 (ko) | 2016-09-23 | 2018-03-29 | 한미약품 주식회사 | 인슐린 수용체와의 결합력이 감소된, 인슐린 아날로그 및 이의 용도 |
| KR102629006B1 (ko) | 2017-03-23 | 2024-01-25 | 한미약품 주식회사 | 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도 |
| MX2021007124A (es) * | 2018-12-21 | 2021-08-11 | Hanmi Pharm Ind Co Ltd | Composicion farmaceutica que incluye insulina y glucagon. |
| CA3186427A1 (en) * | 2020-06-11 | 2021-12-16 | Abvance Therapeutics Inc. | Systems, devices, compositions and methods for treating diabetes |
| EP4434536A4 (en) * | 2021-11-19 | 2026-01-07 | Jiangsu Deyuan Pharmaceutical Co Ltd | Stapled Peptide and Its Use |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3837825A1 (de) | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
| US6011007A (en) | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
| US6869930B1 (en) | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
| RO112873B1 (ro) | 1993-09-17 | 1998-01-30 | Novo Nordisk As | Derivati de insulina |
| US5461031A (en) | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
| US5866538A (en) | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
| EP1826216A1 (en) | 1996-08-30 | 2007-08-29 | Novo Nordisk A/S | Glp-1 derivatives |
| EP0929567B1 (en) | 1996-09-09 | 2005-03-02 | Zealand Pharma A/S | Solid-phase peptide synthesis |
| DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
| DE60040333D1 (de) | 1999-03-17 | 2008-11-06 | Novo Nordisk As | Verfahren zur acylierung von peptiden und proteinen |
| AU2002346491A1 (en) | 2001-12-19 | 2003-07-09 | Eli Lilly And Company | Crystalline compositions for controlling blood glucose |
| HUP0700126A2 (en) | 2001-12-20 | 2007-06-28 | Lilly Co Eli | Insulin molecule having protracted time action |
| DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
| WO2004096854A2 (en) | 2003-04-29 | 2004-11-11 | Eli Lilly And Company | Insulin analogs having protracted time action |
| ATE553124T1 (de) | 2005-06-13 | 2012-04-15 | Imp Innovations Ltd | Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten |
| WO2007081824A2 (en) | 2006-01-06 | 2007-07-19 | Case Western Reserve University | Fibrillation resistant proteins |
| EP2471810A1 (en) | 2006-02-22 | 2012-07-04 | Merck Sharp & Dohme Corporation | Oxyntomodulin derivatives |
| ES2554773T3 (es) | 2006-10-04 | 2015-12-23 | Case Western Reserve University | Insulina y análogos de la insulina resistentes a la fibrilación |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| GEP20135944B (en) | 2007-02-15 | 2013-10-25 | Indiana Unversity Research And Tech Corporation | Glucagon/glp-1 receptor co-agonists |
| ATE520714T1 (de) | 2007-06-15 | 2011-09-15 | Zealand Pharma As | Glucagonanaloga |
| EP2930182A1 (en) | 2007-11-20 | 2015-10-14 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
| DE102008003566A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| WO2009087082A2 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil |
| DE102008003568A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| WO2009087081A2 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue insulinderivate mit extrem verzögertem zeit-/wirkungsprofil |
| US8993516B2 (en) | 2008-04-14 | 2015-03-31 | Case Western Reserve University | Meal-time insulin analogues of enhanced stability |
| NZ588857A (en) | 2008-04-22 | 2012-07-27 | Univ Case Western Reserve | Isoform-specific insulin analogue for control blood sugar levels |
| TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| TWI474832B (zh) * | 2008-06-17 | 2015-03-01 | Univ Indiana Res & Tech Corp | 胰高血糖素／ｇｌｐ-１受體共同激動劑 |
| EP2307037A4 (en) * | 2008-06-17 | 2011-08-03 | Univ Indiana Res & Tech Corp | GLUCAGON ANALOGUE WITH IMPROVED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS |
| PL219335B1 (pl) | 2008-07-04 | 2015-04-30 | Inst Biotechnologii I Antybiotyków | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
| ES2552636T3 (es) | 2008-07-31 | 2015-12-01 | Case Western Reserve University | Insulina estabilizada por halógenos |
| WO2010070251A1 (en) * | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| AU2008365556A1 (en) * | 2008-12-15 | 2011-07-21 | Zealand Pharma A/S | Glucagon analogues |
| WO2010070255A1 (en) * | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| WO2010070253A1 (en) * | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| JP5789515B2 (ja) | 2008-12-19 | 2015-10-07 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | インスリン類似体 |
| JP5755566B2 (ja) | 2008-12-19 | 2015-07-29 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | アミド系インスリンプロドラッグ |
| CN101519446A (zh) | 2009-03-31 | 2009-09-02 | 上海一就生物医药有限公司 | 一种重组人胰岛素及其类似物的制备方法 |
| CN104961822A (zh) * | 2009-07-13 | 2015-10-07 | 西兰制药公司 | 酰化胰高血糖素类似物 |
| SG184988A1 (en) * | 2010-04-27 | 2012-11-29 | Zealand Pharma As | Peptide conjugates of glp-1 receptor agonists and gastrin and their use |
| UY33462A (es) * | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
-
2012
- 2012-01-20 PH PH1/2013/501495A patent/PH12013501495A1/en unknown
- 2012-01-20 BR BR112013018269A patent/BR112013018269A2/pt not_active IP Right Cessation
- 2012-01-20 WO PCT/IB2012/000134 patent/WO2012098462A1/en not_active Ceased
- 2012-01-20 CN CN201280005920.1A patent/CN103491975B/zh not_active Expired - Fee Related
- 2012-01-20 MX MX2013008005A patent/MX2013008005A/es not_active Application Discontinuation
- 2012-01-20 TW TW101102724A patent/TW201247702A/zh unknown
- 2012-01-20 JP JP2013549906A patent/JP2014504597A/ja active Pending
- 2012-01-20 US US13/980,087 patent/US20140011733A1/en not_active Abandoned
- 2012-01-20 CA CA2824397A patent/CA2824397A1/en not_active Abandoned
- 2012-01-20 AR ARP120100195A patent/AR085086A1/es unknown
- 2012-01-20 KR KR1020137018388A patent/KR20140043709A/ko not_active Withdrawn
- 2012-01-20 EP EP12704117.6A patent/EP2665487A1/en not_active Withdrawn
- 2012-01-20 PE PE2013001533A patent/PE20140969A1/es not_active Application Discontinuation
- 2012-01-20 AU AU2012208349A patent/AU2012208349A1/en not_active Abandoned
- 2012-01-20 UY UY0001033872A patent/UY33872A/es not_active Application Discontinuation
- 2012-01-20 EA EA201390796A patent/EA201390796A1/ru unknown
- 2012-01-20 SG SG2013055090A patent/SG192038A1/en unknown
- 2012-01-20 MA MA36191A patent/MA34913B1/fr unknown
-
2013
- 2013-06-11 TN TNP2013000251A patent/TN2013000251A1/fr unknown
- 2013-07-11 CO CO13165262A patent/CO6761400A2/es unknown
- 2013-07-19 CL CL2013002085A patent/CL2013002085A1/es unknown
-
2015
- 2015-09-17 US US14/857,067 patent/US20160000883A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN103491975A (zh) | 2014-01-01 |
| AR085086A1 (es) | 2013-09-11 |
| EA201390796A1 (ru) | 2014-07-30 |
| MA34913B1 (fr) | 2014-02-01 |
| EP2665487A1 (en) | 2013-11-27 |
| KR20140043709A (ko) | 2014-04-10 |
| SG192038A1 (en) | 2013-08-30 |
| MX2013008005A (es) | 2013-08-21 |
| TN2013000251A1 (en) | 2014-11-10 |
| CO6761400A2 (es) | 2013-09-30 |
| US20140011733A1 (en) | 2014-01-09 |
| AU2012208349A1 (en) | 2013-07-18 |
| JP2014504597A (ja) | 2014-02-24 |
| PH12013501495A1 (en) | 2013-09-16 |
| WO2012098462A1 (en) | 2012-07-26 |
| TW201247702A (en) | 2012-12-01 |
| US20160000883A1 (en) | 2016-01-07 |
| BR112013018269A2 (pt) | 2017-06-06 |
| CA2824397A1 (en) | 2012-07-26 |
| CL2013002085A1 (es) | 2013-12-06 |
| NZ612719A (en) | 2015-05-29 |
| UY33872A (es) | 2012-08-31 |
| CN103491975B (zh) | 2016-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20140969A1 (es) | Combinacion de analogos del glucagon acilados con analogos de insulina | |
| MX2019008148A (es) | Uso de peptidos glp-1 de accion prolongada. | |
| ECSP14028506A (es) | Nucleósidos de espirooxetano de uracilo | |
| CY1116987T1 (el) | Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις | |
| PE20150900A1 (es) | Derivados de exendida-4 como agonistas duales de glp1/glucagon | |
| BR112013032717A2 (pt) | coagonistas do receptor de glucagon/glp-1 | |
| ECSP11011390A (es) | Compuestos espiro-amidas sustituidas | |
| DOP2014000115A (es) | Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| CL2014000114A1 (es) | Anticuerpo que se une a r-espondina 1 humana (rspo1); polipéptido que comprende un anticuerpo; composición farmacéutica que comprende el anticuerpo; uso para inhibor el crecimiento de un tumor. | |
| ECSP13012519A (es) | Compuestos sustituidos de benzamida | |
| EA201490070A1 (ru) | Коантагонисты глюкагонового рецептора/glp-1-рецептора | |
| PE20151239A1 (es) | Derivados de exendina-4 funcionalizada | |
| NI201200013A (es) | Composición de insulina de acción prolongada | |
| PE20121130A1 (es) | Analogos de glucagon acilados | |
| AR091837A1 (es) | Compuestos para inmunoterapia dirigida | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| CL2012003226A1 (es) | Compuestos derivados de 5-fluoro-1h-pirazolopiridina ; procedimiento de preparacion de estos; composicion framaceutica que los comprende; y su uso en el tratamiento de enfermedades cardiovasculares, sexuales y metabolicas. | |
| EA201370178A1 (ru) | Стабильные составы для парентеральной инъекции пептидных лекарственных средств | |
| GT201400111A (es) | Triazolopiridinas sustituidas | |
| EA201490037A1 (ru) | Антагонисты trpv4 | |
| EA201691216A1 (ru) | Композиции линаклотида с замедленным высвобождением | |
| EA201400537A1 (ru) | 18-МЕТИЛ-6,7-МЕТИЛЕН-3-ОКСО-17-ПРЕГН-4-ЕН-21,17β-КАРБОЛАКТОНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЭНДОМЕТРИОЗА | |
| AR081819A1 (es) | Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades | |
| EA201590364A1 (ru) | Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда | |
| CL2017000293A1 (es) | Compuestos derivados de benzofurano sustituido en posición 6 por un radical que contiene boro; composición farmacéutica que los comprende; uso en el tratamiento de la hepatitis c (divisional del cl 393-2014) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |